Literature DB >> 28286109

Bullous pemphigoid.

Işın Sinem Bağcı1, Orsolya N Horváth2, Thomas Ruzicka2, Miklós Sárdy3.   

Abstract

Bullous pemphigoid (BP) is the most common autoimmune bullous disorder which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. Collagen XVII and dystonin-e have been identified as target antigens. BP affects mostly the elderly. The incidence of the disease is increasing gradually and is associated with high morbidity and mortality. Clinically, BP is characterized by an intensely pruritic eruption with widespread bullous lesions. The clinical diagnosis can be challenging in the setting of atypical presentations. Diagnosis of BP relies on the integration of clinical, histological, immunopathological, and serological findings. The treatment is mainly based on topical and/or systemic glucocorticoids, but anti-inflammatory antibiotics and steroid sparing adjuvants are useful alternatives. Localised and mild BP can be treated with topical corticosteroids alone.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune bullous diseases; Bullous pemphigoid; Pemphigoid diseases

Mesh:

Substances:

Year:  2017        PMID: 28286109     DOI: 10.1016/j.autrev.2017.03.010

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  32 in total

1.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 3.  [Paraneoplastic autoimmune dermatoses].

Authors:  D Didona; M Hertl
Journal:  Hautarzt       Date:  2021-03-01       Impact factor: 0.751

4.  Tense Bullae and Pruritus.

Authors:  Matthew D Vesely; Brianna A Olamiju; Jonathan S Leventhal
Journal:  Am Fam Physician       Date:  2020-03-01       Impact factor: 3.292

5.  Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.

Authors:  Sian-De Liu; Wei-Ti Chen; Ching-Chi Chi
Journal:  JAMA Dermatol       Date:  2020-08-01       Impact factor: 10.282

6.  Successful Treatment of Bullous Pemphigoid Lesions by Berberine Stamp Therapy: A Case Report and Literature Review.

Authors:  Linyan Cheng; Yi Wang; Hanzhi Lu; Wanjun Guo; Ge Yan; Jianyong Zhu; Dongjie Guo; Fulun Li
Journal:  Front Med (Lausanne)       Date:  2022-07-01

Review 7.  IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Authors:  Maartje G Huijbers; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

8.  Dapsone-responsive inflammatory dermatitis with features of subcorneal pustular dermatosis and bullous pemphigoid.

Authors:  Shilpa Ghatnekar; Audrey Rutherford; Travis Vandergriff; Kim B Yancey
Journal:  JAAD Case Rep       Date:  2022-02-03

Review 9.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

10.  May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature.

Authors:  Michela Ileen Biondo; Chiara Fiorentino; Severino Persechino; Antonella Tammaro; Angela Koverech; Armando Bartolazzi; Salvatore Raffa; Marco Canzoni; Andrea Picchianti-Diamanti; Roberta Di Rosa; Giovanni Di Zenzo; Enrico Scala; Giorgia Meneguzzi; Claudia Ferlito; Milica Markovic; Sara Caporuscio; Maria Laura Sorgi; Simonetta Salemi; Bruno Laganà
Journal:  Microorganisms       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.